Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs, a Canadian specialty pharmaceutical company, has filed a new drug submission for Trelstar 22.5mg.
Subscribe to our email newsletter
Trelstar 22.5mg is a six-month slow release, injectable, luteinizing hormone-releasing hormone agonist indicated for the palliative treatment of advanced prostate cancer.
Paladin obtained the Canadian license for Trelstar from Watson Pharma, a subsidiary of Watson Pharmaceuticals in May 2005.
Jonathan Goodman, president and CEO of Paladin Labs, said: “Trelstar is an important component of Paladin’s urology franchise and this new dosage form will further strengthen this portfolio.”